Table 4.
Logistic Regression Analysis for Presence of Obese Stage B MHD Phenotype
| OR (95% CI) | P Value | |
|---|---|---|
| GAL3 | ||
| Model 1: Age and sex | 1.28 (1.03–1.59) | 0.004 |
| Model 2: Clinical risk model | 1.24 (1.01–1.53) | 0.05 |
| Model 3: Model 1+FSTL3a+NT‐proBNPa | 1.30 (1.01–1.68) | 0.04 |
| FSTL3a | ||
| Model 1: Age and sex | 0.71 (0.57–1.36) | 0.56 |
| Model 2: Clinical risk model | 0.84 (0.53–1.35) | 0.47 |
| Model 3: Model 1+GAL3+NT‐proBNPa | 0.67 (0.41–1.10) | 0.11 |
| NT‐proBNPa | ||
| Model 1: Age and sex | 1.39 (0.85–2.28) | 0.19 |
| Model 2: Clinical risk model | 1.32 (0.83–2.11) | 0.24 |
| Model 3: Model 1+GAL3+FSTL3a | 1.49 (0.89–2.49) | 0.13 |
Clinical risk model: history of hypertension, diabetes mellitus, hyperlipidemia, waist circumference, and estimated glomerular filtration rate in addition to biomarker of interest. FSTL3 indicates follistatin‐like 3 peptide; GAL3, galectin–3; MHD, metabolic heart disease; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; OR, odds ratio.
a
FSTL3 and NT‐proBNP were log‐transformed in regression models for data normalization. OR for both biomarkers reflect 1‐SD increase in log‐transformed biomarker.